Peripherally Acting Drugs held a 62.86% share of the anti-obesity medication market in 2025, reflecting their established role in weight management where treatment acceptance often depends on tolerability and sustained use. Their leadership is aided by practical prescribing patterns that favor mechanisms acting outside the central nervous system, especially in a market where clinicians and patients weigh efficacy alongside day-to-day treatment adherence. This position is reinforced by familiarity in use and their fit within broader obesity management approaches that require long-term medication continuity.

Centrally Acting Drugs are emerging as the fastest-growing segment in the anti-obesity medication market as treatment demand shifts toward options that more directly influence appetite regulation and eating behavior. Their momentum is being influenced by growing interest in therapies that address the neurological drivers of obesity, particularly where patients require stronger intervention than peripheral approaches may offer. Relative to alternatives, Centrally Acting Drugs are gaining traction because they align with evolving clinical emphasis on more targeted metabolic and behavioral control within pharmacological obesity treatment.

Distribution Channel Segment Analysis: Retail Pharmacies (Largest Segment) vs Hospital Pharmacies (Fastest-Growing Segment)

In 2025, Retail Pharmacies accounted for a 58.7% share of the anti-obesity medication market, underscoring their central role in routine prescription fulfillment for chronic weight management therapies. Their leading share is sustained by broad consumer accessibility, convenient refill patterns, and their integration into ongoing outpatient care, which is critical in a market defined by repeated dispensing rather than episodic treatment. Retail settings also remain the most practical touchpoint for patients managing anti-obesity medication over longer treatment durations.

Hospital Pharmacies represent the fastest-growing distribution channel in the anti-obesity medication market as obesity treatment becomes more closely linked with supervised clinical care and institution-led prescribing pathways. Their growth is aided by rising use of anti-obesity therapies in patients who require closer medical oversight, particularly when treatment decisions are tied to comorbidity management or specialist evaluation. Compared with retail channels, Hospital Pharmacies are gaining momentum because they are better positioned within structured care environments where newer or more closely monitored therapies are initiated.